Adaptation of international guidelines for metastatic colorectal cancer: An Asian consensus

Clinical Colorectal Cancer

Volumn 13, Issue 3, 2014, Pages 145-155

  Cheng, Ann Lii ^a   Li, Jin ^b   Vaid, Ashok K ^c   Ma, Brigette Buig Yue ^d   Teh, Catherine ^e   Ahn, Joong B ^f   Bello, Maximino ^g   Charoentum, Chaiyut ^h   Chen, Li Tzong ⁱ   De Lima Lopes, Gilberto ^j,k   Ho, Gwo F ^l   Kong, Hwai L ^m   Lam, Ka O ⁿ   Liu, Tian S ^o   Park, Young S ^p   Sriuranpong, Virote ^q   Sudoyo, Aru W ^r   Wang, Jaw Yuan ⁱ   Zhang, Jun ^s   Zhang, Su Z ^t   Ciardiello, Fortunato ^u   Köhne, Clause Henning ^v   Shaw, Michael ^w   Kim, Tae Won ^x   more..

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c Medical Oncology and Haematology Medanta Cancer Institute   (India)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e MAKATI MEDICAL CENTER   (Philippines)

^f Yonsei University College of Medicine   (South Korea)

^g ST LUKE S MEDICAL CENTER   (Philippines)

^h CHIANG MAI UNIVERSITY   (Thailand)

ⁱ KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^j and Oncoclinicas Do Brasil   (Brazil)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF MALAYA   (Malaysia)

^m HL Kong Medical Oncology Centre Pte Ltd Paragon Medical   (Singapore)

ⁿ UNIVERSITY OF HONG KONG   (Hong Kong)

^o FUDAN UNIVERSITY   (China)

^p Samsung Medical Center   (South Korea)

^q CHULALONGKORN UNIVERSITY   (Thailand)

^r UNIVERSITY OF INDONESIA   (Indonesia)

^s SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^t ZHEJIANG UNIVERSITY   (China)

^u SECOND UNIVERSITY OF NAPLES   (Italy)

^v KLINIKUM OLDENBURG   (Germany)

^w MScript Ltd East Sussex   (United Kingdom)

^x University of Ulsan College of Medicine   (South Korea)

more..

Author keywords

Asia; Chemotherapy; Epidermal growth factor receptor (EGFR) specific monoclonal antibody; KRAS; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GIMERACIL; IRINOTECAN; OTERACIL; OXALIPLATIN; PANITUMUMAB; TEGAFUR; UFT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG COMBINATION; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN; S 1 (COMBINATION);

ADVANCED CANCER; ARTICLE; ASIAN; BIOLOGICAL THERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COLON CANCER; CONSENSUS DEVELOPMENT; DRUG EFFICACY; HUMAN; INOPERABLE CANCER; INOPERABLE SYNCHRONOUS METASTASIS; LIVER METASTASIS; LUNG METASTASIS; MAINTENANCE THERAPY; METACHRONOUS METASTASIS; METASTASIS; METASTATIC COLORECTAL CANCER; MULTIMODALITY CANCER THERAPY; ONCOGENE K RAS; PATIENT SELECTION; PERITONEUM METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RECTUM CANCER; WILD TYPE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ASIA; COLONIC NEOPLASMS; COMPUTER ASSISTED TOMOGRAPHY; DRUG COMBINATION; GENETICS; LIVER NEOPLASMS; LUNG NEOPLASMS; METASTASIS RESECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RECTAL NEOPLASMS; SECONDARY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIA; CAMPTOTHECIN; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG COMBINATIONS; FLUOROURACIL; GUIDELINE ADHERENCE; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; METASTASECTOMY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; PRACTICE GUIDELINES AS TOPIC; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS; TEGAFUR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84908126534     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2014.06.004     Document Type: Note

References (28)

1. J. Ferlay, H.R. Shin, and F. Bray Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. J. Ferlay, H.R. Shin, and F. Bray GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2010 International Agency for Research on Cancer Lyon, France Available at: http://globocan.iarc.fr Accessed January 15, 2013
3. R. Adam, A. De Gramont, and J. Figueras The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus Oncologist 17 2012 1225 1239
4. G. Ku, I.B. Tan, and T. Yau Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012 Lancet Oncol 13 2012 e470 e481
5. J.J. Sung, J.Y. Lau, and K.L. Goh Increasing incidence of colorectal cancer in Asia: implications for screening Lancet Oncol 6 2005 871 876
6. H. Le, A. Ziogas, and J. Zell Survival in colorectal cancer with Asian ethnicity (abstract 4042) J Clin Oncol 26 suppl 2008
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Colon cancer, version 3.2013. Available at: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#site. Accessed January 15, 2013.
8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Rectal cancer, version 4.2013. Available at: http://www.nccn.org/professionals/physician-gls/pdf/rectal.pdf. Accessed January, 15 2013.
9. H.J. Schmoll, E. Van Cutsem, and A. Stein ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision-making Ann Oncol 23 2012 2479 2516
10. R. Adam, D.G. Haller, and G. Poston Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer-an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009 Ann Oncol 21 2010 1579 1584
11. C. Tournigand, T. André, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237
12. G. Folprecht, T. Gruenberger, and W.O. Bechstein Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised Phase 2 trial Lancet Oncol 11 2010 38 47
13. G.Y. Ku, B.A. Haaland, and G. de Lima Lopes Jr. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters Cancer Chemother Pharmacol 70 2012 231 238
14. A. Falcone, S. Ricci, and I. Brunetti Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J Clin Oncol 25 2007 1670 1676
15. G. Masi, F. Loupakis, and L. Pollina Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases Ann Surg 249 2009 420 425
16. J. Cassidy, L. Saltz, and C. Twelves Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients Ann Oncol 22 2011 2604 2609
17. A. Tsunoda, N. Yasuda, and K. Nakao Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer Oncology 77 2009 192 196
18. E. Vasile, G. Masi, and L. Fornaro A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer Br J Cancer 100 2009 1720 1724
19. Y. Komatsu, S. Yuki, and S. Sogabe Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302) Oncology 80 2011 70 75
20. L.C. Ye, T.S. Liu, and L. Ren Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases J Clin Oncol 31 2013 1931 1938
21. E. Van Cutsem, C.H. Köhne, and I. Láng Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 29 2011 2011 2019
22. K. Muro, N. Boku, and Y. Shimada Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study) Lancet Oncol 11 2010 853 860
23. Y.S. Hong, Y.S. Park, and H.Y. Lim S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority Phase 3 trial Lancet Oncol 13 2012 1125 1132
24. C. Bokemeyer, I. Bondarenko, and J.T. Hartmann Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 22 2011 1535 1546
25. C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
26. K. Bujko, M.P. Nowacki, and A. Nasierowska-Guttmejer Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer Br J Surg 93 2006 1215 1223
27. S.Y. Ngan, B. Burmeister, and R.J. Fisher Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04 J Clin Oncol 30 2012 3827 3833
28. D. Delbeke, and W.H. Martin PET and PET-CT for evaluation of colorectal carcinoma Semin Nucl Med 34 2004 209 223